Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EBT (2020 - 2025)

Historic EBT for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.2 million.

  • Ovid Therapeutics' EBT rose 1319.43% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.3 million, marking a year-over-year decrease of 1178.12%. This contributed to the annual value of -$26.4 million for FY2024, which is 4949.66% up from last year.
  • Per Ovid Therapeutics' latest filing, its EBT stood at -$12.2 million for Q3 2025, which was up 1319.43% from -$4.7 million recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' EBT ranged from a high of $176.5 million in Q1 2021 and a low of -$26.3 million during Q4 2021
  • Moreover, its 5-year median value for EBT was -$12.0 million (2022), whereas its average is -$1.9 million.
  • Per our database at Business Quant, Ovid Therapeutics' EBT surged by 98121.21% in 2021 and then tumbled by 15497.01% in 2025.
  • Quarter analysis of 5 years shows Ovid Therapeutics' EBT stood at -$26.3 million in 2021, then soared by 56.34% to -$11.5 million in 2022, then crashed by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then tumbled by 31.4% to -$12.2 million in 2025.
  • Its EBT was -$12.2 million in Q3 2025, compared to -$4.7 million in Q2 2025 and -$10.2 million in Q1 2025.